The FDA has approved RoxyBond abuse-deterrent oxycodone hydrochloride tablets for the management of severe pain. The drug has multiple physical and chemical barriers that make it “more difficult and/or less rewarding” to abuse via intranasal or IV routes. RoxyBond is the first immediate release opioid approved by the FDA for abuse deterrent labeling. Some FDA panelists noted that abuse-deterrence mechanisms still have insufficient post-marketing data.
Read more via Pain Medicine News here.